Celator Pharmaceuticals has started enrolling patients in a late-stage trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with high-risk acute myeloid leukemia. The multicenter trial will be carried out in the U.S. and Canada. "The initiation of this study is an important milestone for CPX-351 and for Celator. We hope the data it provides will allow us to seek regulatory approval for CPX-351," Celator CEO Scott Jackson said.
Published in Brief: